Compare Stocks: NMAD, PBYI, LRMR, and RZLT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LRMR Larimar Therapeutics	$4.32 -0.9%	$3.74	$2.71 ▼ $6.42	$448.76M	0.81	2.80 million shs	882,744 shs
NMAD Lixte Biotechnology	$3.90 -3.7%	$7.36	$2.36 ▼ $8.38	$73.99M	1.29	196,377 shs	114,644 shs
PBYI Puma Biotechnology	$8.82 -0.1%	$7.98	$4.30 ▼ $9.40	$455.29M	1.22	347,217 shs	191,898 shs
RZLT Rezolute	$4.68 +1.7%	$4.76	$1.07 ▼ $11.46	$450.64M	0.58	2.36 million shs	534,238 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LRMR Larimar Therapeutics	0.00%	+4.81%	+17.84%	+34.57%	+8.73%
NMAD Lixte Biotechnology	0.00%	0.00%	0.00%	+59.79%	+109.19%
PBYI Puma Biotechnology	0.00%	-0.90%	+3.52%	+29.66%	+54.10%
RZLT Rezolute	0.00%	-1.92%	-0.22%	+41.98%	-29.23%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LRMR Larimar Therapeutics	$4.32 -0.9%	$3.74	$2.71 ▼ $6.42	$448.76M	0.81	2.80 million shs	882,744 shs
NMAD Lixte Biotechnology	$3.90 -3.7%	$7.36	$2.36 ▼ $8.38	$73.99M	1.29	196,377 shs	114,644 shs
PBYI Puma Biotechnology	$8.82 -0.1%	$7.98	$4.30 ▼ $9.40	$455.29M	1.22	347,217 shs	191,898 shs
RZLT Rezolute	$4.68 +1.7%	$4.76	$1.07 ▼ $11.46	$450.64M	0.58	2.36 million shs	534,238 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LRMR Larimar Therapeutics	0.00%	+4.81%	+17.84%	+34.57%	+8.73%
NMAD Lixte Biotechnology	0.00%	0.00%	0.00%	+59.79%	+109.19%
PBYI Puma Biotechnology	0.00%	-0.90%	+3.52%	+29.66%	+54.10%
RZLT Rezolute	0.00%	-1.92%	-0.22%	+41.98%	-29.23%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LRMR Larimar Therapeutics	3.10	Buy	$11.67	166.36% Upside
NMAD Lixte Biotechnology	1.00	Sell	N/A	N/A
PBYI Puma Biotechnology	2.00	Hold	$6.00	-31.82% Downside
RZLT Rezolute	2.50	Moderate Buy	$9.38	99.47% Upside

Current Analyst Ratings Breakdown

Latest NMAD, PBYI, LRMR, and RZLT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	PBYI Puma Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/7/2026	PBYI Puma Biotechnology	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$5.00 ➝ $6.00
8/5/2026	LRMR Larimar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$12.00 ➝ $11.00
7/30/2026	RZLT Rezolute	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/17/2026	LRMR Larimar Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	RZLT Rezolute	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/16/2026	RZLT Rezolute	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/2/2026	LRMR Larimar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$10.00
6/30/2026	LRMR Larimar Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/30/2026	LRMR Larimar Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$7.00 ➝ $5.00
6/15/2026	RZLT Rezolute	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$6.00 ➝ $11.00

(Data available from 8/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$0.94 per share	N/A
NMAD Lixte Biotechnology	N/A	N/A	N/A	N/A	$1.05 per share	N/A
PBYI Puma Biotechnology	$231.24M	1.96	$0.83 per share	10.59	$2.59 per share	3.40
RZLT Rezolute	N/A	N/A	N/A	N/A	$1.86 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LRMR Larimar Therapeutics	-$165.67M	-$1.95	N/A	N/A	N/A	N/A	-137.39%	-97.65%	11/5/2026 (Estimated)
NMAD Lixte Biotechnology	-$6.01M	-$1.00	N/A	N/A	N/A	N/A	-134.91%	-95.61%	N/A
PBYI Puma Biotechnology	$31.11M	$0.52	16.92	80.00	N/A	11.50%	20.76%	13.22%	11/5/2026 (Estimated)
RZLT Rezolute	-$74.41M	-$0.82	N/A	N/A	N/A	N/A	-58.82%	-54.48%	9/16/2026 (Estimated)

Latest NMAD, PBYI, LRMR, and RZLT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2026	Q2 2026	PBYI Puma Biotechnology	$0.04	$0.19	+$0.15	$0.16	$53.00 million	$56.50 million
8/4/2026	Q2 2026	LRMR Larimar Therapeutics	-$0.3815	-$0.30	+$0.0815	-$0.30	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A
NMAD Lixte Biotechnology	N/A	N/A	N/A	N/A	N/A
PBYI Puma Biotechnology	N/A	N/A	N/A	N/A	N/A
RZLT Rezolute	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LRMR Larimar Therapeutics	N/A	4.70	4.70
NMAD Lixte Biotechnology	N/A	2.78	2.78
PBYI Puma Biotechnology	N/A	2.91	2.64
RZLT Rezolute	N/A	15.84	15.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LRMR Larimar Therapeutics	91.92%
NMAD Lixte Biotechnology	5.10%
PBYI Puma Biotechnology	61.29%
RZLT Rezolute	82.97%

Insider Ownership

Company	Insider Ownership
LRMR Larimar Therapeutics	4.00%
NMAD Lixte Biotechnology	7.30%
PBYI Puma Biotechnology	22.20%
RZLT Rezolute	14.78%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LRMR Larimar Therapeutics	30	103.88 million	99.73 million	Optionable
NMAD Lixte Biotechnology	4	18.97 million	13.59 million	Not Optionable
PBYI Puma Biotechnology	200	51.62 million	40.16 million	Optionable
RZLT Rezolute	40	96.29 million	82.06 million	Optionable

NMAD, PBYI, LRMR, and RZLT Headlines

Recent News About These Companies

Bank of New York Mellon Corp Sells 481,913 Shares of Rezolute, Inc. $RZLT

August 17 at 3:21 AM | marketbeat.com

Rezolute, Inc. $RZLT Shares Acquired by Dimensional Fund Advisors LP

August 14 at 3:28 AM | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Boston Scientific (BSX)

July 30, 2026 | theglobeandmail.com

Rezolute, Inc. (NASDAQ:RZLT) Receives Consensus Recommendation of "Moderate Buy" from Analysts

July 25, 2026 | marketbeat.com

Affinity Asset Advisors LLC Sells 803,503 Shares of Rezolute, Inc. $RZLT

July 25, 2026 | marketbeat.com

Siren L.L.C. Acquires New Position in Rezolute, Inc. $RZLT

July 24, 2026 | marketbeat.com

Jennison Associates LLC Buys New Position in Rezolute, Inc. $RZLT

July 22, 2026 | marketbeat.com

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

July 21, 2026 | globenewswire.com

Rezolute (NASDAQ:RZLT) Cut to "Strong Sell" at Zacks Research

July 18, 2026 | marketbeat.com

Rezolute Inc.

June 29, 2026 | marketwatch.com

FDA Grants Orphan Drug Designation to Rezolute's Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

June 25, 2026 | stockhouse.com

Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society

June 17, 2026 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Rezolute (RZLT) and Vericel (VCEL)

June 12, 2026 | theglobeandmail.com

Positive Signs As Multiple Insiders Buy Rezolute Stock

June 10, 2026 | finance.yahoo.com

RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?

June 4, 2026 | zacks.com

Rezolute, Inc. Announces Four Presentations at the 2026 Annual Meeting of the Endocrine Society on Ersodetug for Congenital Hyperinsulinism

June 4, 2026 | quiverquant.comQ

Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society

June 4, 2026 | globenewswire.com

Analysts Are Bullish on These Healthcare Stocks: Rezolute (RZLT), Relay Therapeutics (RLAY)

June 3, 2026 | theglobeandmail.com

Rezolute upgraded at Citizens after late-stage trial data for lead asset

June 3, 2026 | seekingalpha.com

Rezolute rises after late-stage trial update

June 3, 2026 | msn.com

Rezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease Study

June 2, 2026 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMAD, PBYI, LRMR, and RZLT Company Descriptions

Larimar Therapeutics NASDAQ:LRMR

$4.32 -0.04 (-0.92%)

As of 04:00 PM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Lixte Biotechnology NASDAQ:NMAD

$3.90 -0.15 (-3.70%)

As of 04:00 PM Eastern

LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

Puma Biotechnology NASDAQ:PBYI

$8.82 -0.01 (-0.11%)

As of 04:00 PM Eastern

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Rezolute NASDAQ:RZLT

$4.68 +0.08 (+1.74%)

As of 04:00 PM Eastern

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NMAD, PBYI, LRMR, and RZLT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NMAD, PBYI, LRMR, and RZLT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NMAD, PBYI, LRMR, and RZLT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMAD, PBYI, LRMR, and RZLT Company Descriptions

Larimar Therapeutics NASDAQ:LRMR

Lixte Biotechnology NASDAQ:NMAD

Puma Biotechnology NASDAQ:PBYI

Rezolute NASDAQ:RZLT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NMAD, PBYI, LRMR, and RZLT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NMAD, PBYI, LRMR, and RZLT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NMAD, PBYI, LRMR, and RZLT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NMAD, PBYI, LRMR, and RZLT Company Descriptions

Larimar Therapeutics NASDAQ:LRMR

Lixte Biotechnology NASDAQ:NMAD

Puma Biotechnology NASDAQ:PBYI

Rezolute NASDAQ:RZLT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools